Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Dec;9(6):390-8.
doi: 10.1007/s11916-005-0018-3.

The use of opioids in the treatment of osteoarthritis: when, why, and how?

Affiliations
Review

The use of opioids in the treatment of osteoarthritis: when, why, and how?

Jeremy L R Goodwin et al. Curr Pain Headache Rep. 2005 Dec.

Abstract

As life expectancy increases every decade, the incidence and prevalence of osteoarthritis (OA) also will increase. Despite progress in our knowledge of the pathophysiology of OA, the management of OA-mediated pain continues to challenge physicians. Concern regarding the cardiovascular effects of cyclooxygenase-2 inhibitors and the gastrointestinal and renal side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in general has limited the use of these medications in the management of chronic non-cancer pain. Appropriately dosed and monitored use of opioids for OA pain, when more conservative methods have failed, has potentially fewer life-threatening complications associated with it than the more commonly and often less successfully employed pharmacotherapeutic approaches to care. When used as part of a multimodal approach to pain control, opioids are a safe and effective treatment for joint pain, including that of OA. Patients for whom NSAIDs are contraindicated, or for whom combined acetaminophen, tramadol, and NSAID therapy is ineffective, may be started on low-dose opioids and titrated as needed and tolerated. Patient education and informed consent, exercise, complementary medicine, and the use of a controlled substance agreement increases the likelihood of patient compliance with treatment guidelines, improving functional capacity and quality of life.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pharmacoepidemiol Drug Saf. 2005 Dec;14(12):851-9 - PubMed
    1. BMJ. 2004 Dec 4;329(7478):1317 - PubMed
    1. MMWR Morb Mortal Wkly Rep. 1999 May 7;48(17):349-53 - PubMed
    1. J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S24-30; discussion S31-4 - PubMed
    1. Arthritis Rheum. 1998 May;41(5):778-99 - PubMed

MeSH terms

LinkOut - more resources